Lung squamous cell carcinoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:06:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Lung squamous cell carcinoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effect of Ivonescimab, Pemetrexed, and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation After Previous Treatment https://clinicaltrials.eu/trial/study-on-the-effect-of-ivonescimab-pemetrexed-and-carboplatin-in-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-mutation-after-previous-treatment/ Wed, 29 Apr 2026 14:23:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-ivonescimab-pemetrexed-and-carboplatin-in-patients-with-advanced-non-small-cell-lung-cancer-with-egfr-mutation-after-previous-treatment/ This clinical trial is focused on studying a type of lung cancer known as non-small cell lung cancer (NSCLC) that has specific changes in the epidermal growth factor receptor (EGFR) gene. This type of cancer is called EGFR-mutant NSCLC. The study is for patients whose cancer has advanced locally or spread to other parts of the body and who have not responded to previous treatments with drugs called EGFR tyrosine kinase inhibitors (TKIs). The trial aims to evaluate the effectiveness of a new treatment combination involving a study drug known as ivonescimab (also referred to as AK112 or SMT112) along with two chemotherapy drugs, pemetrexed and carboplatin. Some patients will receive a placebo instead of ivonescimab, combined with the same chemotherapy drugs.

The purpose of the study is to compare the overall survival and progression-free survival of patients receiving the combination of ivonescimab, pemetrexed, and carboplatin with those receiving the placebo, pemetrexed, and carboplatin. The study will be conducted in a double-blind manner, meaning neither the patients nor the researchers will know who is receiving the study drug or the placebo. This helps ensure that the results are not biased. The treatment will be administered through an intravenous drip, which means the medication is given directly into a vein over a period of time.

Participants in the study will receive treatment for a maximum period of 24 weeks, with regular monitoring to assess the effectiveness and safety of the treatment. The study will also evaluate the presence of any side effects and the body’s immune response to the study drug. The trial is expected to continue until the end of 2025, with the goal of providing valuable information on the potential benefits of this new treatment combination for patients with EGFR-mutant NSCLC.

]]>